Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
LONDON - N4 Pharma plc (AIM:N4P), a UK biotech company developing Nuvec, a proprietary gene delivery system for advanced therapies, will release its unaudited interim results for the six months ended June 30, 2025, on Thursday, September 25, according to a company press release.
The company has scheduled an online analyst briefing at 9:30 am on the same day, which will be hosted by Chief Executive Officer Nigel Theobald. Analysts interested in attending should contact Northstar Communications.
Additionally, N4 Pharma will hold an investor presentation at 2:00 pm on September 25 to discuss the interim results. The presentation will be open to all existing and potential shareholders, with questions accepted either in advance through the Investor Meet Company platform until 9:00 am on September 24 or during the live event.
N4 Pharma is focused on developing its Nuvec technology, which is designed to enable advanced therapies for cancer and other diseases. The company is listed on London’s AIM market.
The announcement did not provide any details about the expected financial performance or operational highlights that will be covered in the upcoming results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.